Company Filing History:
Years Active: 2003
Title: Rinku Ahuja: Innovator in Radiolabeled Peptide Technology
Introduction
Rinku Ahuja is a notable inventor based in Ghaziabad, India. He has made significant contributions to the field of medical imaging and therapy through his innovative work on radiolabeled peptide analogs. His research focuses on enhancing diagnostic and therapeutic techniques for targeting specific tumors in mammalian systems.
Latest Patents
Rinku Ahuja holds a patent for "Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotherapy." This invention encompasses radiolabeled peptide analogs of vasoactive intestinal peptide (VIP) that are labeled with a radionuclide. These analogs are useful for imaging target sites within living systems. The invention provides VIP derivatives that selectively bind to the VIP receptor on target cells. It relates to the radiolabeling of VIP-receptor specific agents and their use for radiodiagnostic and radiotherapeutic purposes. The methods for radiolabeling these peptides with radionuclides and their application as scintigraphic imaging agents are also included. The radiolabeled VIP derivatives exhibit pharmacological activity, making them valuable for visualizing VIP-receptor positive tumors and metastases, as well as for treating such tumors in vivo.
Career Highlights
Rinku Ahuja is associated with the Dabur Research Foundation, where he continues to advance his research in peptide technology. His work has implications for improving cancer diagnosis and treatment, showcasing his commitment to innovation in the medical field.
Collaborations
Rinku has collaborated with notable colleagues such as Anand C. Burman and Sudhanand Prasad, contributing to a dynamic research environment that fosters innovation and development in peptide technology.
Conclusion
Rinku Ahuja's contributions to the field of radiolabeled peptides represent a significant advancement in medical diagnostics and therapy. His innovative work continues to pave the way for improved treatment options for patients with specific tumors.